|
| 37985357 | The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study. | Cancer | 2024 |
| 36127572 | Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: Results from a nationwide cohort. | Cancer Med | 2023 |
| 37951019 | Corrigendum to "HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort" [Modern Pathology 36(4) 100087]. | Mod Pathol | 2023 |
| 37777518 | Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients. | NPJ Breast Cancer | 2023 |
| 37925965 | External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer. | Eur J Cancer | 2023 |
| 37326801 | Comparison and predictors of implantable cardioverter-defibrillator therapy for primary and secondary prevention. | Neth Heart J | 2023 |
| 36788086 | HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort. | Mod Pathol | 2023 |
| 36788064 | Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study. | Mod Pathol | 2023 |
| 36769287 | Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. | Int J Mol Sci | 2023 |
| 35267560 | Functional Ex Vivo Tissue-Based Chemotherapy Sensitivity Testing for Breast Cancer. | Cancers (Basel) | 2022 |
| 35353548 | Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. | J Clin Oncol | 2022 |
| 35662306 | Synchronization of repolarization after cardiac resynchronization therapy: A combined clinical and modeling study. | J Cardiovasc Electrophysiol | 2022 |
| 35662281 | Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. | Oncogene | 2022 |
| 36137393 | Selecting patients with HER2-low breast cancer: Getting out of the tangle. | Eur J Cancer | 2022 |
| 35933885 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model. | Eur J Cancer | 2022 |
| 35902644 | HER2-low breast cancer shows a lower immune response compared to HER2-negative cases. | Sci Rep | 2022 |
| 35954426 | External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices. | Cancers (Basel) | 2022 |
| 36375389 | Real-world data of HER2-low metastatic breast cancer: A population based cohort study. | Breast | 2022 |
| 34889530 | Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. | J Pathol Clin Res | 2022 |
| 32929565 | Elastosis in ERα-positive male breast cancer. | Virchows Arch | 2021 |
| 33920880 | Circular RNA in Chemonaive Lymph Node Negative Colon Cancer Patients. | Cancers (Basel) | 2021 |
| 35076865 | Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast. | J Mammary Gland Biol Neoplasia | 2021 |
| 34440000 | Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells. | Biology (Basel) | 2021 |
| 34638394 | Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. | Cancers (Basel) | 2021 |
| 34510716 | A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer. | Mol Oncol | 2021 |
| 34593530 | Ovarian Cancer-Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. | Clin Cancer Res | 2021 |
| 34218258 | Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. | Mod Pathol | 2021 |
| 34312396 | Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. | NPJ Breast Cancer | 2021 |
| 33122801 | Correction: Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent. | Mod Pathol | 2021 |
| 31018242 | A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. | Int J Cancer | 2020 |
| 32058674 | Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification. | Mol Oncol | 2020 |
| 31653758 | Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast. | J Clin Pathol | 2020 |
| 31649042 | Clonality, Antigen Recognition, and Suppression of CD8<sup>+</sup> T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. | Clin Cancer Res | 2020 |
| 33339858 | Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer. | Sci Rep | 2020 |
| 32578065 | Radioactive Seed Versus Wire-Guided Localization for Ductal Carcinoma in Situ of the Breast: Comparable Resection Margins. | Ann Surg Oncol | 2020 |
| 32188473 | High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer. | Breast Cancer Res | 2020 |
| 32279280 | Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. | Breast Cancer Res Treat | 2020 |
| 32182822 | Loss of Y-Chromosome during Male Breast Carcinogenesis. | Cancers (Basel) | 2020 |
| 32333294 | The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers. | Breast Cancer Res Treat | 2020 |
| 32341499 | Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent. | Mod Pathol | 2020 |
| 31534203 | Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. | Mod Pathol | 2020 |
| 31375764 | Ductal carcinoma in situ of the breast: immune cell composition according to subtype. | Mod Pathol | 2020 |
| 30528044 | The role of routine histopathology after chest-contouring surgery in transmen. | Eur J Surg Oncol | 2019 |
| 35100677 | Direct Ex Vivo Observation of Homologous Recombination Defect Reversal After DNA-Damaging Chemotherapy in Patients With Metastatic Breast Cancer. | JCO Precis Oncol | 2019 |
| 31847907 | Prediction and clinical utility of a contralateral breast cancer risk model. | Breast Cancer Res | 2019 |
| 31357602 | <i>APOBEC3B</i> Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer. | Cancers (Basel) | 2019 |
| 31043383 | Correction: Functional <i>Ex Vivo</i> Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. | Clin Cancer Res | 2019 |
| 30921768 | Promoter hypermethylation in ductal carcinoma in situ of the male breast. | Endocr Relat Cancer | 2019 |
| 30756285 | Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material. | Breast Cancer Res Treat | 2019 |
| 30844755 | PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. | Endocr Relat Cancer | 2019 |